Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 16% of the time (3,151 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 16.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painpostoperativepartialnausea andundergoing
  Phrases that lowered it: patientsdexamethasonewomensingle doseapplication
• Primary purpose: prevention (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 93.6% (raises risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 24.7% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor's past trials: 6 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 6 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports before start: 13714 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia. NCT01679093 · started 2009 · scored riskier than 12% of active trials completed
• Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores NCT02372812 · started 2014 · scored riskier than 7% of active trials completed
• Dexamethasone With Super-hydration for Prevention of Postoperative Nausea and Vomiting NCT02726308 · started 2015 · scored riskier than 11% of active trials completed
• Effect of Steroids on Post-tonsillectomy Morbidities NCT02401529 · started 2013 · scored riskier than 6% of active trials completed
• Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV NCT06428084 · started 2023 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.